HOLLAND POUNCEY: Open Payments
NPI 1447617147 · LUVERNE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,328 in 68 payments from 17 companies in 2025. Trend: 2023 $1,057 · 2024 $1,357 · 2025 $1,328
Food & beverage: $1,328
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 10 | $212 |
| ABBVIE INC. | 11 | $178 |
| Axsome Therapeutics, Inc. | 4 | $112 |
| AstraZeneca Pharmaceuticals LP | 6 | $106 |
| Neurocrine BioSciences, Inc. | 5 | $101 |
| PFIZER INC. | 4 | $74 |
| GlaxoSmithKline, LLC. | 4 | $73 |
| Novo Nordisk Inc | 4 | $73 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $69 |
| Phathom Pharmaceuticals, Inc. | 5 | $65 |
Products named: REXULTI, VRAYLAR, Auvelity, INGREZZA, TRELEGY ELLIPTA, BREZTRI, CAPLYTA, VOQUEZNA.
Industry payments across AL — which companies pay providers there.
